Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-2870 versus physician's choice chemotherapy in recurrent or metastatic cervical cancer after platinum-based therapy and immunotherapy
MOH_2024-05-21_013426Phase 3Active, not recruiting
- Sponsor
- אנטון גרשטיין
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in Cervical Cancer (CC) (3 arms), sponsored by אנטון גרשטיין. Primary endpoints: Objective response rate, Safety and tolerability and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on MOH_2024-05-21_013426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-21_013426.